



Grand Challenges Canada®
Grands Défis Canada

TRANSITION-TO-SCALE HEALTH IMPACT QUESTIONNAIRE

This Health Impact Questionnaire will be evaluated through a scientific peer review managed independently by the Canadian Institutes of Health Research (CIHR), based on the Independent Scientific Review Criteria outlined in Transition-to-Scale (TTS) Request for Proposals (RFP) Section 4.5. The result of this review is an important input to the recommendations put forward by GCC management, the GCC Investment Committee (if applicable) and to final funding decisions. GCC may incorporate reviewer comments and concerns into the due diligence process and deal structuring, which includes milestones and risk mitigation strategies.

Institution/organization Legal name:	
Country of institution:	
Implementation Country	
Project title:	
Project Lead, Full Name	
Name of Organization:	
Country of Organization:	
Email:	
Phone:	
Address:	
Date of Submission	

1. GLOBAL HEALTH CHALLENGE

Describe the scope and magnitude of the global health problem you are targeting. Include in this description any known trends in distribution or health determinants, and the economic and health burdens of this problem, to provide context.

2. INNOVATION

I. Describe your innovation and how it works, specifying any key scientific or technological elements. Identify which aspects have already been tested and which still need to be demonstrated.

II. What are the novel elements of your innovation? Explain how your idea is substantially different from other approaches to address the stated problem and how it improves upon the best existing alternatives. If alternatives exist, please provide specific examples for comparison.

III. Describe the target population of your innovation, including any information you have on socio-economic status and/or why this group could be considered a disadvantaged group. Describe the interaction of the target population with the innovation and the innovation's intended impact in terms of its reach and impact on that target population. Describe how this innovation fits into the current context in the region where it will be implemented.

3. PROOF OF CONCEPT

Describe the proof of concept of your innovation. Present sufficient and credible evidence to substantiate that your innovative idea has demonstrated improved health outcome(s) and/or the reduction of significant barrier(s) to health and demand for the solution in a controlled or limited setting. Describe your results achieved to date, including key outcomes and outputs (see, for example, Sections 5. I, II, and III below), and including the methodologies used to obtain and analyze those results. If possible (e.g., if your proof of concept was funded through one of the Targeted Challenges at GCC, i.e., Global Mental Health, Saving Lives at Birth, or Saving Brains), attach your most recently updated core metrics spreadsheet.

4. EXPECTED HEALTH OUTCOMES AND OUTPUTS (TTS PHASE)

Describe the expected health and developmental impact of your innovation (i) over the next phase of your project for which you are requesting TTS funds (please define this time period) and (ii) in the longer term (beyond this immediate next phase); i.e., what are the expected end results?

In the tables below, describe the outcomes and outputs you expect your project to achieve over the next phase of your project (same time period as question above). You may replicate the relevant table(s) as needed where several indicators will be tracked for a particular type of outcomes (e.g., for "lives improved" a project might have distinct indicators/anticipated numbers for each of children and mothers).

I. ULTIMATE OUTCOMES

Consider including the following information in the data source row where applicable:

- Assessment tool(s) used
- Frequency and timing of assessments
- Threshold used to determine significant change/improve
- Sample size and characteristics of control and intervention arms
- Information on baseline and/or treatment as usual

A. Lives saved in low- and middle-income countries (LMICs) (# of lives saved)

Expected outcomes in numbers:	
Indicator:	
Data Source:	

B. Lives improved in LMICs (# people with improved health outcomes)

Expected outcomes in numbers:	
Indicator:	
Data Source:	

II. INTERMEDIATE OUTCOMES

Consider including the following information in the data source row where applicable:

- Type of treatment or service being accessed
- Definition of access and distinction, if any, from use
- Treatment access or service coverage baseline and expected change attributable to the project
- Known effect size of the innovation being accessed (i.e., if the innovation reaches the target population, what will the impact be on the individuals reached?).
- Assumptions regarding adherence/acceptance of treatment (e.g., How is adherence defined? What proportion of those accessing the intervention is expected to use it as intended? What are the foreseeable obstacles to adherence?)
- Definition(s) of beneficiaries and/or intermediaries
- Description of how quality will be monitored among intermediaries providing services

A. Lives Touched - BENEFICIARIES who accessed a product and/or service (# of beneficiaries who accessed products and / or services)

Expected outcomes in numbers:	
Indicator:	
Data Source:	

B. Lives Touched - INTERMEDIARIES who accessed a product and/or service and improved their knowledge/attitudes/behaviours (# of intermediaries who accessed products and/or services)

Expected outcomes in numbers:	
Indicator:	
Data Source:	

III. OUTPUTS

A. Building Tools and Capacity to Execute (e.g., # of innovative prototypes and/or service delivery models developed, # of relevant policies developed and/or adopted, # of intermediaries who will receive training as part of the project, # of jobs created)

Expected outcomes in numbers:	
Indicator:	
Data Source:	

5. MONITORING AND EVALUATION PLAN

Outline how you plan to track impact during the Transition-to-Scale process. Provide a narrative of the specific evaluation methods and tools you will use. Describe how the plan to monitor and evaluate health impacts is sufficiently robust to draw appropriate conclusions by the end of funding. Include the following information:

- *How information will be gathered:* an overview of data collection methods, who is responsible for gathering the data, and frequency or timing of data collection.
- *What information will be gathered:* the data collection tools that will be used, what is measured with the tools, and how “improvement” is defined.
- *Where it will be gathered:* a brief description of the locations (geographical), as well as number and characteristics of the specific sites (i.e., clinics, hospitals, etc).
- *Who it will be gathered from:* a description of the target population, including the beneficiaries/participants, intermediaries, intervention and/or control groups. Include your sample size and a description how beneficiaries/participants will be selected.
- *Data analysis approach and methods.*

--

6. TEAM COMPOSITION

List the members of the project team and their key qualifications (i.e. those most relevant to their role in this project). You may add rows and/or attach CVs if deemed necessary.

NAME	AFFILIATION	PROJECT ROLE	QUALIFICATIONS